カテゴリー： Allied Market Research, 世界, 医療/バイオ

コンパニオンアニマル関節炎の世界市場2021-2031：機会分析・産業予測

◆英語タイトル：Companion Animal Arthritis Market By Companion Type (Dog, Cat, Horse), By Arthritis Type (Osteoarthritis, Rheumatoid Arthritis), By Treatment (Exercise, Medical, Others), By Distribution Channel (Online Store, Pet Supply Store, Veterinary Hospitals and Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Allied Market Researchが発行した調査報告書（ALD23MC013）◆商品コード：ALD23MC013
◆発行会社（リサーチ会社）：Allied Market Research
◆発行日：2023年1月
◆ページ数：298
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

アライドマーケットリサーチ社の市場調査書では、世界のコンパニオンアニマル関節炎市場について調査・分析を行い、イントロダクション、エグゼクティブサマリー、市場概要、コンパニオン種類別（犬、猫、馬）分析、関節炎種類別（変形性関節症、関節リウマチ）分析、治療法別（運動、医療、その他）分析、流通チャネル別（オンラインストア、ペット用品店、動物病院・診療所、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）分析、競争状況、企業情報などの内容を掲載しています。なお、当書には、Covetrus, Inc.、Zoetis、Elanco、Virbac、Dechra Pharmaceuticals plc、Vetoquinol Animal Health Pvt Ltd、Phibro Animal Health Corp、Boehringer Ingelheim GmbH、Bayer AG、Ceva Sante Animaleなどの企業情報が含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界のコンパニオンアニマル関節炎市場規模：コンパニオン種類別
- 犬における市場規模
- 猫における市場規模
- 馬における市場規模
・世界のコンパニオンアニマル関節炎市場規模：関節炎種類別
- 変形性関節症の市場規模
- 関節リウマチの市場規模
・世界のコンパニオンアニマル関節炎市場規模：治療法別
- 運動における市場規模
- 医療における市場規模
- その他治療法における市場規模
・世界のコンパニオンアニマル関節炎市場規模：流通チャネル別
- オンラインストアチャネルの市場規模
- ペット用品店チャネルの市場規模
- 動物病院・診療所チャネルの市場規模
- その他チャネルの市場規模
・世界のコンパニオンアニマル関節炎市場規模：地域別
- 北米のコンパニオンアニマル関節炎市場規模
- ヨーロッパのコンパニオンアニマル関節炎市場規模
- アジア太平洋のコンパニオンアニマル関節炎市場規模
- 中南米/中東・アフリカのコンパニオンアニマル関節炎市場規模
・競争状況
・企業情報

The spread of arthritis is very common and more rapid among the companion animal population. This is the most common type of degenerative joint disease, generally known as osteoarthritis. Joints offer elastic connections and protective cushioning between bones.

Osteoarthritis causes bone growth inside joints, as well as fluid accumulation and cartilage loss. This can cause discomfort, joint deterioration, and reduced mobility over time for companion animals. A large number of medications are being introduced to the market to treat. These factors are anticipated to drive the companion animal arthritis market growth in the upcoming years. The rise in the prevalence of arthritis among pets such as dogs and cats which cause inflammation of joints is estimated to drive the companion animal arthritis market size.

The veterinary nonsteroidal anti-inflammatory drugs (NSAIDs) used for the treatment of arthritis in companion animals have a negative impact on the health of companion animals. For instance, in dogs and cats, veterinary NSAIDs can cause diarrhea, vomiting, and ulcers in the stomach and intestine. These factors are anticipated to hamper the companion animal arthritis market share during the forecast period.

The ongoing research activities for the development of therapeutic treatment for arthritis condition among animal is estimated to generate excellent growth opportunities in the market. For instance, research on companion dogs with naturally occurring illnesses inevitably provides information on how to reduce pain in companion pet dogs. Such knowledge, when paired with the safety data obtained by canine work, can serve as the foundation for a veterinary therapeutic development program. All these factors are projected to create several growth opportunities in the market.

The COVID-19 pandemic negatively impacted the companion animal arthritis market. The COVID-19 pandemic resulted in the establishment of strict lockdown and quarantine laws throughout the globe, which further restricted non-essential veterinary visits. Furthermore, the delay in medical operations has a significant impact on animal arthritis treatment. However, the introduction of the COVID-19 pandemic has increased pet adoption and foster applications, which is expected to help market expansion during the forecast period.

The key players profiled in this report include Zoetis, Virbac, Elanco, Boehringer Ingelheim International GmbH, Ceva, Dechra Pharmaceuticals PLC., Vetoquinol, NexGen Pharmaceuticals, and Norbrook.

Key Benefits For Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the companion animal arthritis market analysis from 2021 to 2031 to identify the prevailing companion animal arthritis market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the companion animal arthritis market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global companion animal arthritis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Companion Type
● Dog
● Cat
● Horse

By Arthritis Type
● Osteoarthritis
● Rheumatoid Arthritis

By Treatment
● Exercise
● Medical
● Others

By Distribution Channel
● Online Store
● Pet Supply Store
● Veterinary Hospitals and Clinics
● Others

By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ UK
○ France
○ Spain
○ Italy
○ Rest of Europe
● Asia-Pacific
○ China
○ Japan
○ India
○ South Korea
○ Australia
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ United Arab Emirates
○ South Africa
○ Rest of LAMEA

● Key Market Players
○ Covetrus, Inc.
○ Zoetis
○ Elanco
○ Virbac
○ Dechra Pharmaceuticals plc
○ Vetoquinol Animal Health Pvt Ltd
○ Phibro Animal Health Corp
○ Boehringer Ingelheim GmbH
○ Bayer AG
○ Ceva Sante Animale

❖ レポートの目次 ❖

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.2.Restraints
3.4.3.Opportunities
3.5.COVID-19 Impact Analysis on the market
3.6.Value Chain Analysis
3.7.Key Regulation Analysis
3.8.Patent Landscape
3.9.Regulatory Guidelines
3.10.Market Share Analysis
CHAPTER 4: COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2. Dog
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3. Cat
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4. Horse
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
CHAPTER 5: COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2. Osteoarthritis
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3. Rheumatoid Arthritis
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT
6.1 Overview
6.1.1 Market size and forecast
6.2. Exercise
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3. Medical
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4. Others
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL
7.1 Overview
7.1.1 Market size and forecast
7.2. Online Store
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market share analysis by country
7.3. Pet Supply Store
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market share analysis by country
7.4. Veterinary Hospitals and Clinics
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market share analysis by country
7.5. Others
7.5.1 Key market trends, growth factors and opportunities
7.5.2 Market size and forecast, by region
7.5.3 Market share analysis by country
CHAPTER 8: COMPANION ANIMAL ARTHRITIS MARKET, BY REGION
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key trends and opportunities
8.2.2 North America Market size and forecast, by Companion Type
8.2.3 North America Market size and forecast, by Arthritis Type
8.2.4 North America Market size and forecast, by Treatment
8.2.5 North America Market size and forecast, by Distribution Channel
8.2.6 North America Market size and forecast, by country
8.2.6.1 U.S.
8.2.6.1.1 Key market trends, growth factors and opportunities
8.2.6.1.2 Market size and forecast, by Companion Type
8.2.6.1.3 Market size and forecast, by Arthritis Type
8.2.6.1.4 Market size and forecast, by Treatment
8.2.6.1.5 Market size and forecast, by Distribution Channel
8.2.6.2 Canada
8.2.6.2.1 Key market trends, growth factors and opportunities
8.2.6.2.2 Market size and forecast, by Companion Type
8.2.6.2.3 Market size and forecast, by Arthritis Type
8.2.6.2.4 Market size and forecast, by Treatment
8.2.6.2.5 Market size and forecast, by Distribution Channel
8.2.6.3 Mexico
8.2.6.3.1 Key market trends, growth factors and opportunities
8.2.6.3.2 Market size and forecast, by Companion Type
8.2.6.3.3 Market size and forecast, by Arthritis Type
8.2.6.3.4 Market size and forecast, by Treatment
8.2.6.3.5 Market size and forecast, by Distribution Channel
8.3 Europe
8.3.1 Key trends and opportunities
8.3.2 Europe Market size and forecast, by Companion Type
8.3.3 Europe Market size and forecast, by Arthritis Type
8.3.4 Europe Market size and forecast, by Treatment
8.3.5 Europe Market size and forecast, by Distribution Channel
8.3.6 Europe Market size and forecast, by country
8.3.6.1 Germany
8.3.6.1.1 Key market trends, growth factors and opportunities
8.3.6.1.2 Market size and forecast, by Companion Type
8.3.6.1.3 Market size and forecast, by Arthritis Type
8.3.6.1.4 Market size and forecast, by Treatment
8.3.6.1.5 Market size and forecast, by Distribution Channel
8.3.6.2 UK
8.3.6.2.1 Key market trends, growth factors and opportunities
8.3.6.2.2 Market size and forecast, by Companion Type
8.3.6.2.3 Market size and forecast, by Arthritis Type
8.3.6.2.4 Market size and forecast, by Treatment
8.3.6.2.5 Market size and forecast, by Distribution Channel
8.3.6.3 France
8.3.6.3.1 Key market trends, growth factors and opportunities
8.3.6.3.2 Market size and forecast, by Companion Type
8.3.6.3.3 Market size and forecast, by Arthritis Type
8.3.6.3.4 Market size and forecast, by Treatment
8.3.6.3.5 Market size and forecast, by Distribution Channel
8.3.6.4 Spain
8.3.6.4.1 Key market trends, growth factors and opportunities
8.3.6.4.2 Market size and forecast, by Companion Type
8.3.6.4.3 Market size and forecast, by Arthritis Type
8.3.6.4.4 Market size and forecast, by Treatment
8.3.6.4.5 Market size and forecast, by Distribution Channel
8.3.6.5 Italy
8.3.6.5.1 Key market trends, growth factors and opportunities
8.3.6.5.2 Market size and forecast, by Companion Type
8.3.6.5.3 Market size and forecast, by Arthritis Type
8.3.6.5.4 Market size and forecast, by Treatment
8.3.6.5.5 Market size and forecast, by Distribution Channel
8.3.6.6 Rest of Europe
8.3.6.6.1 Key market trends, growth factors and opportunities
8.3.6.6.2 Market size and forecast, by Companion Type
8.3.6.6.3 Market size and forecast, by Arthritis Type
8.3.6.6.4 Market size and forecast, by Treatment
8.3.6.6.5 Market size and forecast, by Distribution Channel
8.4 Asia-Pacific
8.4.1 Key trends and opportunities
8.4.2 Asia-Pacific Market size and forecast, by Companion Type
8.4.3 Asia-Pacific Market size and forecast, by Arthritis Type
8.4.4 Asia-Pacific Market size and forecast, by Treatment
8.4.5 Asia-Pacific Market size and forecast, by Distribution Channel
8.4.6 Asia-Pacific Market size and forecast, by country
8.4.6.1 China
8.4.6.1.1 Key market trends, growth factors and opportunities
8.4.6.1.2 Market size and forecast, by Companion Type
8.4.6.1.3 Market size and forecast, by Arthritis Type
8.4.6.1.4 Market size and forecast, by Treatment
8.4.6.1.5 Market size and forecast, by Distribution Channel
8.4.6.2 Japan
8.4.6.2.1 Key market trends, growth factors and opportunities
8.4.6.2.2 Market size and forecast, by Companion Type
8.4.6.2.3 Market size and forecast, by Arthritis Type
8.4.6.2.4 Market size and forecast, by Treatment
8.4.6.2.5 Market size and forecast, by Distribution Channel
8.4.6.3 India
8.4.6.3.1 Key market trends, growth factors and opportunities
8.4.6.3.2 Market size and forecast, by Companion Type
8.4.6.3.3 Market size and forecast, by Arthritis Type
8.4.6.3.4 Market size and forecast, by Treatment
8.4.6.3.5 Market size and forecast, by Distribution Channel
8.4.6.4 South Korea
8.4.6.4.1 Key market trends, growth factors and opportunities
8.4.6.4.2 Market size and forecast, by Companion Type
8.4.6.4.3 Market size and forecast, by Arthritis Type
8.4.6.4.4 Market size and forecast, by Treatment
8.4.6.4.5 Market size and forecast, by Distribution Channel
8.4.6.5 Australia
8.4.6.5.1 Key market trends, growth factors and opportunities
8.4.6.5.2 Market size and forecast, by Companion Type
8.4.6.5.3 Market size and forecast, by Arthritis Type
8.4.6.5.4 Market size and forecast, by Treatment
8.4.6.5.5 Market size and forecast, by Distribution Channel
8.4.6.6 Rest of Asia-Pacific
8.4.6.6.1 Key market trends, growth factors and opportunities
8.4.6.6.2 Market size and forecast, by Companion Type
8.4.6.6.3 Market size and forecast, by Arthritis Type
8.4.6.6.4 Market size and forecast, by Treatment
8.4.6.6.5 Market size and forecast, by Distribution Channel
8.5 LAMEA
8.5.1 Key trends and opportunities
8.5.2 LAMEA Market size and forecast, by Companion Type
8.5.3 LAMEA Market size and forecast, by Arthritis Type
8.5.4 LAMEA Market size and forecast, by Treatment
8.5.5 LAMEA Market size and forecast, by Distribution Channel
8.5.6 LAMEA Market size and forecast, by country
8.5.6.1 Brazil
8.5.6.1.1 Key market trends, growth factors and opportunities
8.5.6.1.2 Market size and forecast, by Companion Type
8.5.6.1.3 Market size and forecast, by Arthritis Type
8.5.6.1.4 Market size and forecast, by Treatment
8.5.6.1.5 Market size and forecast, by Distribution Channel
8.5.6.2 Saudi Arabia
8.5.6.2.1 Key market trends, growth factors and opportunities
8.5.6.2.2 Market size and forecast, by Companion Type
8.5.6.2.3 Market size and forecast, by Arthritis Type
8.5.6.2.4 Market size and forecast, by Treatment
8.5.6.2.5 Market size and forecast, by Distribution Channel
8.5.6.3 United Arab Emirates
8.5.6.3.1 Key market trends, growth factors and opportunities
8.5.6.3.2 Market size and forecast, by Companion Type
8.5.6.3.3 Market size and forecast, by Arthritis Type
8.5.6.3.4 Market size and forecast, by Treatment
8.5.6.3.5 Market size and forecast, by Distribution Channel
8.5.6.4 South Africa
8.5.6.4.1 Key market trends, growth factors and opportunities
8.5.6.4.2 Market size and forecast, by Companion Type
8.5.6.4.3 Market size and forecast, by Arthritis Type
8.5.6.4.4 Market size and forecast, by Treatment
8.5.6.4.5 Market size and forecast, by Distribution Channel
8.5.6.5 Rest of LAMEA
8.5.6.5.1 Key market trends, growth factors and opportunities
8.5.6.5.2 Market size and forecast, by Companion Type
8.5.6.5.3 Market size and forecast, by Arthritis Type
8.5.6.5.4 Market size and forecast, by Treatment
8.5.6.5.5 Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2021
CHAPTER 10: COMPANY PROFILES
10.1 Covetrus, Inc.
10.1.1 Company overview
10.1.2 Key Executives
10.1.3 Company snapshot
10.1.4 Operating business segments
10.1.5 Product portfolio
10.1.6 Business performance
10.1.7 Key strategic moves and developments
10.2 Zoetis
10.2.1 Company overview
10.2.2 Key Executives
10.2.3 Company snapshot
10.2.4 Operating business segments
10.2.5 Product portfolio
10.2.6 Business performance
10.2.7 Key strategic moves and developments
10.3 Elanco
10.3.1 Company overview
10.3.2 Key Executives
10.3.3 Company snapshot
10.3.4 Operating business segments
10.3.5 Product portfolio
10.3.6 Business performance
10.3.7 Key strategic moves and developments
10.4 Virbac
10.4.1 Company overview
10.4.2 Key Executives
10.4.3 Company snapshot
10.4.4 Operating business segments
10.4.5 Product portfolio
10.4.6 Business performance
10.4.7 Key strategic moves and developments
10.5 Dechra Pharmaceuticals plc
10.5.1 Company overview
10.5.2 Key Executives
10.5.3 Company snapshot
10.5.4 Operating business segments
10.5.5 Product portfolio
10.5.6 Business performance
10.5.7 Key strategic moves and developments
10.6 Vetoquinol Animal Health Pvt Ltd
10.6.1 Company overview
10.6.2 Key Executives
10.6.3 Company snapshot
10.6.4 Operating business segments
10.6.5 Product portfolio
10.6.6 Business performance
10.6.7 Key strategic moves and developments
10.7 Phibro Animal Health Corp
10.7.1 Company overview
10.7.2 Key Executives
10.7.3 Company snapshot
10.7.4 Operating business segments
10.7.5 Product portfolio
10.7.6 Business performance
10.7.7 Key strategic moves and developments
10.8 Boehringer Ingelheim GmbH
10.8.1 Company overview
10.8.2 Key Executives
10.8.3 Company snapshot
10.8.4 Operating business segments
10.8.5 Product portfolio
10.8.6 Business performance
10.8.7 Key strategic moves and developments
10.9 Bayer AG
10.9.1 Company overview
10.9.2 Key Executives
10.9.3 Company snapshot
10.9.4 Operating business segments
10.9.5 Product portfolio
10.9.6 Business performance
10.9.7 Key strategic moves and developments
10.10 Ceva Sante Animale
10.10.1 Company overview
10.10.2 Key Executives
10.10.3 Company snapshot
10.10.4 Operating business segments
10.10.5 Product portfolio
10.10.6 Business performance
10.10.7 Key strategic moves and developments



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ コンパニオンアニマル関節炎の世界市場2021-2031：機会分析・産業予測(Companion Animal Arthritis Market By Companion Type (Dog, Cat, Horse), By Arthritis Type (Osteoarthritis, Rheumatoid Arthritis), By Treatment (Exercise, Medical, Others), By Distribution Channel (Online Store, Pet Supply Store, Veterinary Hospitals and Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • コンパニオンアニマル関節炎の世界市場2022-2031：機会分析・産業予測
  • クリ・デュ・チャット症候群治療の世界市場2021-2031：機会分析・産業予測
  • 月経痛治療の世界市場2021-2031：機会分析・産業予測
  • 胃がん の世界市場2021-2031：機会分析・産業予測
  • 子宮内膜症の世界市場2021-2031：機会分析・産業予測

    • ◆H&Iグローバルリサーチのお客様（例）◆